Inverna Therapeutics

@invernatx.com

114 Followers 429 Following

Next-generation RNA splicing modulation platform dedicated to transforming patient outcomes in severe genetic diseases #RNAtherapeutics #RNAsplicingmodulation #Pseudoexon #Parkinsons #Huntingtons

🌟 Inverna is heading to San Francisco! 🌟

We’re thrilled to announce that Inverna and our CEO, Poul Sørensen, will be attending the annual JPM Week, one of the most prestigious events in the biotech and healthcare industry.

This marks an exciting opportunity for Inverna to share our vision and connect with industry leaders, innovators, and collaborators. As we continue our work in developing disease-modifying therapeutics for Huntington’s disease through our novel RNA splicing modulation platform, we are eager to engage with those who share our passion for groundbreaking science.

📅 If you’re attending the conference and would like to discuss partnerships, innovation, or simply learn more about our journey, we’d love to meet you!

Let’s build the future of biotech together.

Press release for Inverna Therapeutics, a novel Danish biotech company at the forefront of innovative RNA therapeutics, today announced its launch as a leading-edge RNA therapeutics company. The Company was co-founded by the University of Southern Denmark and Argobio and is dedicated to transforming patient outcomes in severe genetic diseases, starting with a lead program addressing Huntington’s disease.

Inverna’s platform originates from the groundbreaking research of Professor Brage Storstein Andresen, an internationally renowned expert in RNA splicing and antisense technology. Inverna aims to overcome the limitations of conventional RNA therapeutics by harnessing the revolutionary potential of sequence-based splice modulation to provide safer and more effective treatments for a wide range of debilitating diseases.